COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,886 Articles (22,568 medRxiv, 8,318 bioRxiv)

Most recent first Previous |  Page 888: Articles 8871-8880  | Next

Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with Coronavirus Disease 19 (COVID-19) from the perspective of National Health Service England
Kilcoyne, A., Jordan, E., Thomas, K., Pepper, A. N., Zhou, A., Chappell, D., Amarapala, M., Theriault, R.-K., Thompson, M.
10.1101/2022.02.11.22270859 — Posted: 2022-02-15
COVID-19 mortality and excess mortality among working-age Californians, by occupational sector: March 2020 through November 2021
Chen, Y.-H., Riley, A. R., Duchowny, K. A., Aschmann, H. E., Chen, R., Kiang, M. V., Mooney, A., Stokes, A. C., Glymour, M. M., Bibbins-Domingo, K.
10.1101/2022.02.14.22270958 — Posted: 2022-02-15
Is this Herpes or Syphilis?: Latent Dirichlet Allocation Analysis of Sexually Transmitted Disease-Related Reddit Posts During the COVID-19 Pandemic
Johnson, A. K., Bhaumik, R., Nandi, D., Roy, A., Mehta, S. D.
10.1101/2022.02.13.22270890 — Posted: 2022-02-15
Reliable estimation of SARS-CoV-2 anti-spike protein IgG titers from single dilution optical density values in serologic surveys
Andrade Belitardo, E. M. M., Nery, N., Aguilar Ticona, J. P., Portilho, M. M., Riberiro, G. S., Reis, M. G., Costa, F., Cummings, D. A. T., Ko, A. I., Fofana, M. O.
10.1101/2022.02.13.22270904 — Posted: 2022-02-15
Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19
Sasaki, M., Tabata, K., Kishimoto, M., Itakura, Y., Kobayashi, H., Ariizumi, T., Uemura, K., Toba, S., Kusakabe, S., Maruyama, Y., Iida, S., Nakajima, N., Suzuki, T., Yoshida, S., Nobori, H., Sanaki, T., Kato, T., Shishido, T., Hall, W. W., Orba, Y., Sato, A., Sawa, H.
10.1101/2022.02.14.480338 — Posted: 2022-02-15
Milk of cow and goat, immunized by recombinant protein vaccine ZF-UZ-VAC2001(Zifivax), contains neutralizing antibodies against SARS-CoV-2 and remains active after standard milk pasteurization
Garib, V., Katsamaki, S., Turdikulova, S. U., Levitskaya, Y., Zakhidova, N., Bus, G., Karamova, K., Rakhmedova, M., Magbulova, N., Bruhov, A., Garib, F. Y., Abdurakhmonov, I. Y.
10.1101/2022.02.14.480298 — Posted: 2022-02-15
Reduced antigenicity of Omicron lowers host serologic response
Tubiana, J., Xiang, Y., Fan, L., Wolfson, H. J., Chen, K., Schneidman-Duhovny, D., Shi, Y.
10.1101/2022.02.15.480546 — Posted: 2022-02-15
A model of persistent post SARS-CoV-2 induced lung disease for target identification and testing of therapeutic strategies
Dinnon, K. H., Leist, S. R., Okuda, K., Dang, H., Fritch, E. J., Gully, K. L., Cruz, G., Evangelista, M. D., Asakura, T., Gilmore, R. C., Hawkins, P., Nakano, S., West, A., Schäfer, A., Gralinski, L. E., Everman, J. L., Sajuthi, S. P., Zweigart, M. R., Dong, S., McBride, J., Cooley, M. R., Hines, J. B., Love, M. K., Groshong, S. D., VanSchoiack, A., Phelan, S. J., Liang, Y., Hether, T., Leon, M., Zumwalt, R. E., Barton, L. M., Duval, E. J., Mukhopadhyay, S., Stroberg, E., Borczuk, A., Thorne, L. B., Sakthivel, M. K., Lee, Y. Z., Hagood, J. S., Mock, J. R., Seibold, M. A., O'Neal, W. K., Montgomery, S. A., Boucher, R. C., Baric, R. S.
10.1101/2022.02.15.480515 — Posted: 2022-02-15
A global lipid map reveals host dependency factors conserved across SARS-CoV-2 variants
Farley, S. E., Kyle, J., Leier, H., Bramer, L. M., Weinstein, J., Bates, T. A., Lee, J.-Y., Metz, T. O., Schultz, C., Tafesse, F.
10.1101/2022.02.14.480430 — Posted: 2022-02-15
A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
Liu, Y., Zhang, X., Liu, J., Xia, H., Zou, J., Muruato, A. E., Periasamy, S., Plante, J. A., Bopp, N. E., Kurhade, C., Bukreyev, A., Ren, P., Wang, T., Menachery, V. D., Plante, K. S., Xie, X., Weaver, S. C., Shi, P.-Y.
10.1101/2022.02.14.480460 — Posted: 2022-02-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).